Valion Bio, Inc. 8-K

What Happened

• Valion Bio, Inc. filed a Current Report on Form 8-K on July 14, 2026 (Item 7.01) to disclose a business update via a press release.
• The press release is furnished as Exhibit 99.1 to the 8-K; the filing also includes the embedded Inline XBRL cover page (Exhibit 104). The report includes the company’s standard forward‑looking statements disclaimer.

Key Details

• Filing date: July 14, 2026 (Form 8-K, Item 7.01 — Regulation FD Disclosure).
• Exhibit: 99.1 — Press release of Valion Bio, Inc., dated July 14, 2026.
• Technical exhibit: 104 — Cover Page Interactive Data File (Inline XBRL).
• The filing contains forward‑looking statements and a caution that actual results may differ due to risks and uncertainties.

Why It Matters

• This 8-K publicly documents a company business update; investors should read the attached press release (Exhibit 99.1) for any new operational or strategic information that could affect the stock.
• The filing does not report earnings, financial statements, or management changes — it is a disclosure of a press release under Regulation FD with forward‑looking language, so any projections or plans in the release are subject to stated risks.
• Retail investors who track material company developments should review the press release and the company’s SEC filings for further details and updated risk disclosures.